UNICREDIT BANK/CALL/MODERNA/100/0.1/19.06.24 | Market Closed - Borsa Italiana 16:04:59 2024-05-29 EDT | ||
| 4.46 EUR | -8.98% |
|
| Current month | +182.21% | ||
| 1 month | +169.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 4.14 | -15.51% |
| 24-05-28 | 4.9 | -21.22% |
| 24-05-27 | 6.22 | +0.97% |
| 24-05-24 | 6.16 | +3.18% |
| 24-05-23 | 5.97 | +1.53% |
Real-time Borsa Italiana
Last update May 29, 2024 at 04:04 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| UD0DQG | |
| ISIN | DE000HD0DQG4 |
| Date issued | 2023-11-01 |
| Strike | 100 $ |
| Maturity | 2024-06-19 (21 Days) |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.4 € |
|---|---|
| Lowest since issue | 0.415 € |
| Spread | 0.01 € |
| Spread % | 0.22% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
147.9
USD
Average target price
138.5
USD
Spread / Average Target
-6.36%
- Stock Market
- Warrants
- UD0DQG Warrant
